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1. INTRODUCTION {#mgg3689-sec-0005}
===============

Liver transplantation is an effective therapy for end‐stage liver diseases and liver failure. Since immunosuppressive agents have been introduced for clinical use, the incidence of allograft rejection decreases dramatically. However, acute rejection episode, normally resulted from inadequate immunosuppression, would still occur among 15%--45% recipients within months (Farges et al., [1996](#mgg3689-bib-0010){ref-type="ref"}; Hubscher, [2009](#mgg3689-bib-0014){ref-type="ref"}; Ingulli, [2010](#mgg3689-bib-0015){ref-type="ref"}). And, it might lead to graft loss, increased risk of chronic organ dysfunction, and suboptimal long‐term outcomes with decreased allograft half‐life by 34% (Ingulli, [2010](#mgg3689-bib-0015){ref-type="ref"}).

Allogeneic grafts induce fierce T cell‐mediated immune responses in recipients, and the response is the main cause of rejection and graft dysfunction (Sanchez‐Fueyo & Strom, [2011](#mgg3689-bib-0036){ref-type="ref"}). T cells from both innate and adaptive immune system play central roles in regulating immune reactions during rejection episode (Clarkson & Sayegh, [2005](#mgg3689-bib-0006){ref-type="ref"}; Ingulli, [2010](#mgg3689-bib-0015){ref-type="ref"}; Rothstein & Sayegh, [2003](#mgg3689-bib-0034){ref-type="ref"}). First, host T cells allorecognize donor‐derived antigens, and are activated by costimulatory signals (Hubscher, [2009](#mgg3689-bib-0014){ref-type="ref"}; Ingulli, [2010](#mgg3689-bib-0015){ref-type="ref"}). During this step, antigens are recognized by the interaction between major histocompatibility complexes (MHC) on antigen‐presenting cells (APC) and T‐cell receptors (TCR) on T cells. Then the recognition stimulates T cells and alters the intracellular transcriptional profiles. Once activated, host T cells would undergo clonal expansion, differentiate into effector T cells, migrate into allograft, and accelerate the destruction of donor organ (Hubscher, [2009](#mgg3689-bib-0014){ref-type="ref"}; Ingulli, [2010](#mgg3689-bib-0015){ref-type="ref"}). It leads to mixed inflammatory cells infiltration, usually mononuclear, in portal tracts, and is the most common histology characteristic of acute rejection (Hubscher, [2009](#mgg3689-bib-0014){ref-type="ref"}).

Recent studies indicated that costimulatory molecules might serve as important therapeutic targets for preventing allograft rejection. For instance, *B7* proteins, belonging to IgG superfamily, normally express on membrane of APCs. The best‐studied *B7* proteins are *CD80* (OMIM \#112203) and *CD86* (OMIM \#601020). Depending on the counterparts engaged on T cells surface, they could provide either positive or negative costimulatory signal. T cells could be positively stimulated by APCs when *CD80* or *CD86* interacts with *CD28* (OMIM \#186760), or negatively stimulated by *CTLA4* (OMIM \#123890) (Clarkson & Sayegh, [2005](#mgg3689-bib-0006){ref-type="ref"}). Commercial recombinant *CTLA4* protein has provided extended graft survival for renal recipients (Dell‐Olio & Kelly, [2010](#mgg3689-bib-0009){ref-type="ref"}; Post, Douglas, & Mulligan, [2005](#mgg3689-bib-0032){ref-type="ref"}; Snanoudj, Zuber, & Legendre, [2010](#mgg3689-bib-0039){ref-type="ref"}).

Initial works on *CD276* (OMIM \#605715) suggested a positive costimulatory effect on T‐cells activation. In conjunction with anti‐CD3 monoclonal antibody, *CD276* positively stimulated T‐cell proliferation, with enhanced *IFN‐*γ production and *CD8 *+* *cytotoxic activity. Although in a cardiac transplantation model, graft rejection developed rapidly in both *CD276*‐/‐ mice and control mice equally, brief treatment of immunosuppressive regimens, to *CD276*‐/‐ mice, led to prolonged survival time and decreased incidence of rejections (L. Wang et al., [2005](#mgg3689-bib-0046){ref-type="ref"}). *CD276* also showed the effect of negative costimulation, such as inhibiting T‐cell activation and effector cytokine production (Clarkson & Sayegh, [2005](#mgg3689-bib-0006){ref-type="ref"}; Rothstein & Sayegh, [2003](#mgg3689-bib-0034){ref-type="ref"}). *TREML2* (Triggering receptor expressed on myeloid cell‐like transcript 2, OMIM \#609715) has been identified as a ligand of *CD276* for positive costimulation (Hashiguchi et al., [2008](#mgg3689-bib-0011){ref-type="ref"}; Kobori et al., [2010](#mgg3689-bib-0019){ref-type="ref"}). Since *CD276* can positively activate T cells via *TREML2*, we speculated a participation of both molecules in graft intolerance.

Nowadays, individualized therapies such as tailored and safe immunosuppression are urgently demanded for organ transplantation. Advanced molecular biological techniques, such as gene array, proteomics researches, mass spectrometry, and genome‐wide association studies (GWAS), are discovering valuable biomarkers, including mRNA, miRNA, protein, small chemical molecules, and genetic signatures \[single nucleotide polymorphism (SNP) SSR, CNV et al.\] (Hernandez‐Fuentes & Lechler, [2010](#mgg3689-bib-0012){ref-type="ref"}; Offit, [2011](#mgg3689-bib-0031){ref-type="ref"}; Rook & Rand, [2011](#mgg3689-bib-0033){ref-type="ref"}). These objectively detectable or measurable molecules and genetic signatures are biologically or pathogenically involved, and might act as parameters for diagnosis and disease staging, as well as indicators or predictors for disease prognosis and clinical response (Hernandez‐Fuentes & Lechler, [2010](#mgg3689-bib-0012){ref-type="ref"}). The analysis of genetic characteristics of a patient would assist in interpreting his/her biological and immune response, and help to depict allograft rejection, so that damages to parenchymal tissues can be diagnosed in advance and prevented before irreversible (Hernandez‐Fuentes & Lechler, [2010](#mgg3689-bib-0012){ref-type="ref"}; Offit, [2011](#mgg3689-bib-0031){ref-type="ref"}).

SNPs of cytokines and costimulatory molecules are associated with acute rejection (de Reuver et al., [2003](#mgg3689-bib-0008){ref-type="ref"}; Hernandez‐Fuentes & Lechler, [2010](#mgg3689-bib-0012){ref-type="ref"}; Kim et al., [2010](#mgg3689-bib-0018){ref-type="ref"};); however, none of these findings has been introduced into identifying the risk of rejection. We wondered whether a quantitative risk assessment model could be deduced, by integrating critical biomarkers, such as genetic polymorphism, and other risk factors. And we expected, by using the model, recipients would receive optimized immunosuppression for individualizing their clinical cares.

In conclusion, we discovered SNPs of costimulatory molecule, *CD276*, as well as its ligand, *TREML2*, were associated with liver grafts acute rejection. Moreover, HBV (hepatitis B virus) infection was also statistically confirmed as a risk factor for acute rejection. Genetic polymorphism influenced the production of *CD276* mRNA. Moreover, by integrating these risk factors, we established a risk assessment model, which categorized recipients into low‐, medium‐, and high‐risk groups.

2. METHODOLOGY {#mgg3689-sec-0006}
==============

2.1. Population {#mgg3689-sec-0007}
---------------

The diagnoses of enrolled recipients included hepatocellular carcinoma, fulminant hepatitis, and decompensate liver cirrhosis (Table [1](#mgg3689-tbl-0001){ref-type="table"}). Recipients with autoimmune hepatitis, or drug‐induced hepatitis, or sclerosing cholangitis, or those underwent a second or subsequent liver transplantation, or multiple organ transplantation were excluded. In the retrospective study, 299 recipients who received liver grafts from 2006 to 2011 were enrolled for the clinical aspects analysis (Table [1](#mgg3689-tbl-0001){ref-type="table"}). However, due to DNA sample quality and limitation of sequencing technology, we used 289 cases, with complete genotype information of total 11 SNPs, to analyze genetic association with acute rejection. The rest 10 cases which lacked genotype information of at least one SNP were excluded in the association analysis. While four of the 10 cases did not lack the genotyping results of rs2127015, rs6915083, and rs7754593, 293 cases were used in the following risk assessment model deduction. Another 89 recipients who received liver grafts from 2011 to 2012 were enrolled for further prospective validation of the risk assessment model. Among them, 11 recipients developed acute rejections. These two cohorts included 345 males and 43 females, aged from 21 to 69 (46.9 ± 9.5) years old.

###### 

Relevance of clinical aspects and characteristics of recipient with acute rejection

                           Acute rejection group (*n* = 43)   Nonrejection group (*n* = 256)   *p* value   OR (95% CI)
  ------------------------ ---------------------------------- -------------------------------- ----------- --------------------
  Age                      48.9 ± 10.2                        46.5 ± 9.0                       0.895       
  Gender (male/female)     38/5                               224/32                           0.872       1.086 (0.40--2.96)
  MELD score               19.1 ± 8.0                         19.8 ± 9.4                       0.776       
  Blood type mismatch      8 (18.6%)                          32 (12.5%)                       0.277       1.600 (0.68--3.75)
  Chronic HBV infection    32 (74.4%)                         143 (55.9%)                      0.0223      2.299 (1.11--4.76)
  Primary disease                                                                                          
  Cirrhosis                36 (83.7%)                         192 (75.0%)                      0.2137      1.714 (0.73--4.04)
  Fulminant Hepatitis      7 (16.3%)                          50 (19.5%)                       0.6154      0.801 (0.34--1.91)
  HCC                      16 (37.2%)                         102 (39.8%)                      0.7436      0.895 (0.46--1.74)
  Comorbidities                                                                                            
  Ascites                  20 (46.5%)                         106 (41.4%)                      0.5304      1.231 (0.64--2.36)
  Hepatorenal syndrome     6 (13.9%)                          22 (8.6%)                        0.2643      1.725 (0.66--4.54)
  Hepatic encephalopathy   3 (6.9%)                           15 (5.9%)                        0.7756      1.205 (0.33--4.35)
  Portal hypertension      2 (4.7%)                           10 (3.9%)                        0.8179      1.200(0.25--5.68)
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All 388 recipients followed a routine triple combination of immunosuppressive regimen, including tacrolimus, corticosteroid, and mycophenolate mofetil. In brief, the minimum level of tacrolimus blood concentration was maintained at 10--12 ng/ml for the first month after transplantation, at 8--10 ng/ml later in the first year, and at 5--8 ng/ml thereafter. Mycophenolate mofetil was administered 1--2 g per day. Corticosteroid treatment was initiated with 1,000 mg prednisolone once during the operation, continued with gradually reduced methylprednisolone starting at 240 mg on day 1 and ending up at 2.5 mg before discontinuation after 2 months (Xu et al., [2011](#mgg3689-bib-0050){ref-type="ref"}; Yu et al., [2011](#mgg3689-bib-0053){ref-type="ref"}).

2.2. Diagnosis of acute rejection {#mgg3689-sec-0008}
---------------------------------

The diagnosis of acute rejection is confirmed by liver biopsy and graded by Banff criteria. Rejection occurred within 6 months was considered as acute rejection (Adeyi, Fischer, & Guindi, [2010](#mgg3689-bib-0001){ref-type="ref"}; Neuhaus et al., [2002](#mgg3689-bib-0029){ref-type="ref"}).

2.3. Ethical Compliance {#mgg3689-sec-0009}
-----------------------

We followed the World Medical Association\'s Declaration of Helsinki. Written informed consents were obtained. The research procedure was approved and supervised by the Ethical Review Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University.

2.4. DNA extraction and genotyping {#mgg3689-sec-0010}
----------------------------------

Genome DNA was extracted from preoperative peripheral blood. Based on the data from Hapmap (<http://www.hapmap.org>), the selection of candidate SNPs of *CD276* and *TREML2* was in accordance with the rule that minor allele frequency and r^2^ should be no less than 20% and 0.8, respectively. Genotyping was performed by SNaPshot (Applied Biosystems, CA). Data were collected by ABI3130xl Genetic Analyzer (Applied Biosystems, CA), and analyzed on GeneMapper 4.0 (Applied Biosystems, CA).

2.5. Detection of *CD276*/*TREML2* mRNA, and membrane *CD276* in PBMCs {#mgg3689-sec-0011}
----------------------------------------------------------------------

Total RNA was extracted from peripheral blood of recipients within 6 months posttransplantation, and cDNA was synthesized by reverse transcription kit (Biorad, CA). We detected the transcripts of *CD276* and *TREML2* on ABI 7500fast (Applied Biosystems, CA) with iQ SYBR Green Supermix PCR kit (Biorad, CA). The primer pairs used in real‐time PCR reaction were listed as follows; *CD276*, forward 5′‐CTCCCTACAGCTCCTACCCTC‐3′, reverse 5′‐TGGTCTGTGTATCGCATCCTT‐3′, based on *CD276* Genbank sequence (NM_001024736.2); *TREML2*, forward 5′‐CCCACAGCCTCATAGATAAGACA‐3′, reverse 5′‐CCATATTGCTTTGTTCCCCTT‐3′, based on *TREML2* Genbank sequence (NM_024807.4); and *GAPDH*, forward 5′‐ATGGGGAAGGTGAAGGTCG‐3′, reverse 5′‐GGGGTCATTGATGGCAACAATA‐3′, based on *GAPDH* Genbank sequence (NM_001256799.2). The relative expression of *CD276* and *TREML2* mRNA was calculated by ΔΔCT method. mRNA expression of both *CD276* and *TREML2* was detected three times in each cDNA sample.

To detect membrane *CD276*, red blood cells were lysed with RBC lysing buffer (eBioscience) from whole blood; subsequently peripheral blood mononuclear cells (PBMCs) were pelleted by density‐gradient centrifugation with Ficoll (Sigma). Cells were incubated with phycoerythrin‐labeled anti‐*CD276* antibody (R&D) and fluorescein isothiocyanate labeled anti‐CD3 antibody (eBioscience) in 2% FBS containing PBS for 30 min at 4°C. A Mouse IgG1, κ (eBioscience) and IgG2a, κ (BD Pharmingen) were used as isotype controls for anti‐*CD276* and anti‐CD3 antibody, respectively. Finally, cells were quantified on a BD LSRII flow cytometry (BD Bioscience) using CellQuest (BD Bioscience), and data were analyzed by FlowJo (Tree Star, Stanford, CA). Membrane expression of *CD276* protein was detected three times in each PBMC sample.

2.6. Comparison of mRNA or protein expression {#mgg3689-sec-0012}
---------------------------------------------

Unpaired t test or one‐way ANOVA test was used for comparison of two groups or more than two groups with Graphpad Prism 6.0 (Graphpad Software, CA). A two‐tailed *p* value less than 0.05 was considered statistically significant.

2.7. Association analysis and establishing risk assessment model {#mgg3689-sec-0013}
----------------------------------------------------------------

Analyses were performed to verify the association between genetic polymorphism and acute rejection by SNPStats (<http://bioinfo.iconcologia.net/snpstats>) or Haploview (<http://www.broad.mit.edu/mpg/haploview>). The relevance of clinical characteristics and acute rejection was confirmed by Fisher\'s exact test by Graphpad Prism 6.0. Variables considered to be statistically significant were subsequently analyzed by multivariable logistic regression using SPSS 20.0 (IBM, IL). The AUROC (area under receiver operating characteristic curve) evaluation was performed by SPSS 20.0 to assess the predictive value of variables and diagnostic accuracy of the model. AUROC value of 0.5 or 1 indicates a bad or good discrimination, respectively (Linden, [2006](#mgg3689-bib-0023){ref-type="ref"}). A *p* value less than 0.05 was considered statistically significant.

3. RESULTS {#mgg3689-sec-0014}
==========

3.1. HBV infection risked acute allograft rejection {#mgg3689-sec-0015}
---------------------------------------------------

The overall incidence of acute rejection within the first half year postoperation was 14.4% (*n* = 43) in 299 recipients, who received their liver grafts from 2006 to 2009. We did not find any clinical relevance between acute rejection and age, gender, primary diseases, or comorbidities of recipients (Table [1](#mgg3689-tbl-0001){ref-type="table"}).

We found recipients, positive with HBV infection, were at higher risk than those negatives (Table [1](#mgg3689-tbl-0001){ref-type="table"}). However, the combination of HBV infection and other diagnoses, or combination between either two of the other diagnoses did not increase the risk of acute rejection (data not shown).

3.2. Genetic polymorphisms of *CD276* and *TREML2* were both associated with acute allograft rejection {#mgg3689-sec-0016}
------------------------------------------------------------------------------------------------------

To illustrate the potential association between genetic polymorphisms of costimulatory molecules and acute allograft rejection, seven candidate SNPs of *CD276* and four of *TREML2* were investigated. Six SNPs of *CD276* located in intron, one in 3′ UTR; while two SNPs of *TREML2* located in intron, the others in 3′ UTR. We found both genetic polymorphisms of *CD276* and *TREML2* were associated with acute allograft rejection. Recipients carrying T allele at rs2127015 of *CD276*, or G allele at rs6915083 or rs7754593 of *TREML2* were at high risk of acute rejection (Table [2](#mgg3689-tbl-0002){ref-type="table"}). Moreover, we performed linkage disequilibrium study to find out haplotype among the SNPs of *CD276* and *TREML2*, or between each other, and identified two haplotype blocks in *CD276* and one in *TREML2*, but none between these two genes (Figure [1](#mgg3689-fig-0001){ref-type="fig"}). However, no association was observed between haplotypes and acute rejection (Table [3](#mgg3689-tbl-0003){ref-type="table"}).

###### 

Association results for SNPs of *CD276* and *TREML2* in acute rejection

  SNP          Events   Genotype Count/frequency   *p* value     OR (95% CI)            
  ------------ -------- -------------------------- ------------- ------------- -------- ---------------
  *CD276*               A/A                        T/A           T/T                    
  rs11072431   AR       7 (16.3%)                  24 (55.8%)    12 (27.9%)    0.1071   
               NAR      75 (30.5%)                 126 (51.2%)   45 (18.3%)             
  *CD276*               A/A                        G/A           G/G                    
  rs11574495   AR       2 (4.7%)                   18 (41.9%)    23 (53.5%)    0.7931   
               NAR      18 (7.3%)                  104 (42.3%)   124 (50.4%)            
  *CD276*               C/C                        C/T           T/T                    
  rs12593558   AR       5 (11.6%)                  20 (46.5%)    18 (41.9%)    0.3265   
               NAR      42 (17.1%)                 128 (52.0%)   76 (30.9%)             
  *CD276*               G/G                        G/T           T/T                    
  rs12594627   AR       22 (51.2%)                 20 (46.5%)    1 (2.3%)      0.2439   
               NAR      113 (45.9%)                109 (44.3%)   24 (9.8%)              
                        C/C                        C/T           T/T                    
               AR       2 (4.7%)                   25 (58.1%)    16 (37.2%)    0.0733   
  *CD276*      NAR      45 (18.3%)                 130 (52.8%)   71 (28.9%)             
  rs2127015             C/C                        C/T+T/T                              
               AR       2 (4.7%)                   41 (95.3%)                  0.0253   0.21
               NAR      45 (18.3%)                 201 (81.7%)                          (0.05--0.93)
  *CD276*               C/C                        C/T           T/T                    
  rs3816661    AR       24 (55.8%)                 17 (39.5%)    2 (4.7%)      0.6933   
               NAR      124 (50.4%)                103 (41.9%)   19 (7.7%)              
  *CD276*               A/A                        G/A           G/G                    
  rs7176654    AR       14 (32.6%)                 23 (53.5%)    6 (13.9%)     0.7775   
               NAR      79 (32.1%)                 122 (49.6%)   45 (18.3%)             
  *TREML2*              A/A                        C/A           C/C                    
  rs4714431    AR       21 (48.8%)                 19 (44.2%)    3 (7.0%)      0.2401   
               NAR      91 (37.0%)                 121 (49.2%)   34 (13.8%)             
                        A/A                        G/A           G/G                    
               AR       3 (7.0%)                   26 (60.5%)    14 (32.6%)    0.0436   
  *TREML2*     NAR      48 (19.5%)                 104 (42.3%)   94 (38.2%)             
  rs6915083             A/A                        G/A+G/G                              
               AR       3 (7.0%)                   40 (93.0%)                  0.0467   0.30
               NAR      48 (19.5%)                 198 (80.5%)                          (0.09--1.04)
                        G/G                        G/T           T/T                    
               AR       23 (53.5%)                 19 (44.2%)    1 (2.3%)      0.0887   
  *TREML2*     NAR      101 (41.1%)                114 (46.3%)   31 (12.6%)             
  rs7754593             G/G+GT                     T/T                                  
               AR       42 (97.7%)                 1 (2.3%)                    0.0476   6.05
               NAR      215 (87.4%)                31 (12.6%)                           (0.80--45.61)
  *TREML2*              A/A                        G/A           G/G                    
  rs9394767    AR       29 (67.4%)                 13 (30.2%)    1 (2.3%)      0.3950   
               NAR      139 (56.5%)                97 (39.4%)    10 (4.1%)              

AR represents acute rejection, while NAR for nonacute rejection.
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![LD plots of *CD276* and *TREML2*. We identified two haplotype blocks, block 1 and block 2, in *CD276*, and one haplotype block, block 3, in *TREML2*](MGG3-7-e689-g001){#mgg3689-fig-0001}

###### 

Association results of haplotypes in acute rejection

  Block     Haplotype   Events   Haplotype   *p* value   OR (95% CI)   
  --------- ----------- -------- ----------- ----------- ------------- --------------
  Block 1   GT          AR       54          32          0.3084        1.27
                        NAR      280         212                       (0.79--2.04)
            AC          AR       20          66          0.3025        0.754
                        NAR      141         351                       (0.44--1.29)
            GC          AR       10          76          0.4896        0.7802
                        NAR      71          421                       (0.38--1.58)
  Block 2   GTC         AR       55          31          0.1258        1.44
                        NAR      271         221                       (0.90--2.32)
            TCT         AR       19          67          0.2093        0.70
                        NAR      141         351                       (0.40--1.21)
            GCC         AR       8           78          0.3370        0.68
                        NAR      64          428                       (0.31--1.48)
            TCC         AR       2           84          0.7142        0.7571
                        NAR      15          477                       (0.17--3.33)
  Block 3   GA          AR       63          23          0.1040        1.52
                        NAR      316         176                       (0.91--2.54)
            TG          AR       16          70          0.2927        0.73
                        NAR      117         375                       (0.40--1.31)
            TA          AR       7           79          0.3000        0.65
                        NAR      59          433                       (0.28--1.47)

AR represents acute rejection, while NAR for nonacute rejection.
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3.3. rs2127015 genotype was associated with the expression of *CD276* {#mgg3689-sec-0017}
---------------------------------------------------------------------

Since rs2127015, rs6915083, and rs7754593 located in either intron or 3′ UTR, these synonymous SNPs might affect mRNA transcription or processing. We detected the expression of both *CD276* and *TREML2* mRNA in PBMCs, and found recipients carrying T allele in rs2127015 with a higher *CD276* mRNA expression (Figure [2](#mgg3689-fig-0002){ref-type="fig"}). Subsequently, we verified membrane *CD276* expression by flow cytometry, and found membrane *CD276* expressed on both *CD3‐* and *CD3 *+* *PBMCs. The percentages of *CD276 *+* *cells were positively correlated in the two subpopulations (correlation coefficient = 0.381, *P *\<* *0.01). Recipients carrying T allele at rs2127015 were with a higher percentage of *CD276 *+* CD3*‐ cells in PBMCs (Figure [3](#mgg3689-fig-0003){ref-type="fig"}).

![*CD276* and *TREML2* mRNA expression in PBMCs. Plots represented relative expression level of mRNA of each individual recipient. The result indicated that T allele carriers of rs2127015 expressed more *CD276* mRNA than the others (*p *\<* *0.05). Bar represented mean ± standard deviation of the scatter plots](MGG3-7-e689-g002){#mgg3689-fig-0002}

![Membrane *CD276* expression in *CD3*‐ PBMCs. Plots represented the percent of *CD276* positive cells in *CD3*‐ PBMCs of each individual recipient. The result indicated that T allele carriers of rs2127015 possessed more *CD276 *+* *cell in *CD3*‐ peripheral blood (*p *\<* *0.05). Bar represented mean ± standard deviation of the scatter plots](MGG3-7-e689-g003){#mgg3689-fig-0003}

![Acute rejection model assessment with ROC curve](MGG3-7-e689-g004){#mgg3689-fig-0004}

3.4. Prediction of acute rejection by combining genetic polymorphisms and HBV infection {#mgg3689-sec-0018}
---------------------------------------------------------------------------------------

Since SNPs of *CD276* and *TREML2*, and HBV infection as well, increased the risk of acute rejection, we performed multivariable logistic regression analysis to verify the possibility of genetic polymorphisms and HBV infection as independent risk factors for acute rejection. Then a risk assessment model of acute rejection was established by the combination between genotype of rs2127015 and HBV infection. The other two associated variables, rs6915083 and rs7754593, which failed the test, were not included. In this model, the risk score was equal to ‐1.122 + 1.493 × rs2127015 + 0.817 × HBV (for rs2127015, T/T and C/T carrier was equal to 1, while C/C was equal to 0; for HBV, HBV infection was equal to 1, otherwise it was equal to 0).

The model exhibited a sensitivity of 69.8%, specificity of 54.7%, and an area under the curve of 0.634 (Figure [2](#mgg3689-fig-0002){ref-type="fig"}). Subsequently, each recipient could be categorized into three groups: the score \> 1, 1 \> the score \> 0, and the score \< 0, which could be considered as high‐, medium‐, and low risk, respectively. According to the model, the incidence of acute rejection was 20.8% (*n* = 30) in high‐risk group (*n* = 144), 11.2% (*n* = 11) in medium‐risk group (*n* = 98), and 4.3% (*n* = 2) in low‐risk group (*n* = 51).

3.5. Validation of the prediction significance of the model by a prospective study {#mgg3689-sec-0019}
----------------------------------------------------------------------------------

To validate the prediction significance and precision of the assessment model, we performed a prospective cohort study with a population of 89 recipients who received their liver grafts from 2010 to 2011. According to their scores, 89 recipients were divided into three groups (high‐risk group with the score \> 1, *n* = 47; medium‐risk group with 1 \> the score \> 0, *n* = 21; low‐risk group with the score \< 0, *n* = 21), then all the recipients were followed up for more than 6 months after transplantation. Finally, 17.0% (*n* = 8) recipients developed acute rejection in the high‐risk group, while that was 9.5% (*n* = 2) and 4.8% (*n* = 1) in the medium‐ and low‐risk group, respectively.

4. DISCUSSION {#mgg3689-sec-0020}
=============

In our current study, we identified several acute rejection‐associated risk factors, including genetic polymorphisms and HBV infection. And, we also provided a semiquantitative risk assessment model, which would facilitate the individualized immunosuppressive therapy for recipients according to the risk group which he/she belonged to. Recipients categorized into the high‐risk group would be suggested a more optimal regimen and frequent surveillance of immunosuppression, while those in the low‐risk group should avoid excessive immunosuppression.

Although the development of acute rejection is complicated, its initiation requires both allorecognition and T‐cell activation (Ingulli, [2010](#mgg3689-bib-0015){ref-type="ref"}; Wood & Goto, [2012](#mgg3689-bib-0049){ref-type="ref"}). Genetic polymorphisms of MHC, costimulatory molecules, and cytokines genes, which involve in the allorecognition and the activation, have been proved to be associated with acute rejection in liver and renal transplantations (Bitetto et al., [2012](#mgg3689-bib-0002){ref-type="ref"}; Jiang et al., [2007](#mgg3689-bib-0017){ref-type="ref"}; Tapirdamaz et al., [2006](#mgg3689-bib-0044){ref-type="ref"}; Zhu, Huang, Liu, & Xie, [2012](#mgg3689-bib-0058){ref-type="ref"}).

The fact that *CD80*,*CD86,* and their ligands involving in acute rejection (Marder et al., [2003](#mgg3689-bib-0024){ref-type="ref"}; Marin et al., [2005](#mgg3689-bib-0025){ref-type="ref"}), imply *CD276* and *TREML2* would be worth studying as well. Unlike other *B7*s, *CD276* expresses in a wide range of human organs both transcriptionally and translationally. Recent studies also proved an upregulation of *CD276* in different types of cancers and tumor‐infiltrating blood vessels, including colon cancer, prostate cancer, pancreatic cancer, and liver cancer (Sun et al., [2010](#mgg3689-bib-0042){ref-type="ref"}; Sun et al., [2012](#mgg3689-bib-0043){ref-type="ref"}; Yuan et al., [2011](#mgg3689-bib-0054){ref-type="ref"}; Zhao et al., [2013](#mgg3689-bib-0056){ref-type="ref"}), suggesting *CD276* as an attractive and desirable target for cancer immunotherapy (Seaman et al., [2017](#mgg3689-bib-0038){ref-type="ref"}). In addition, *CD276* promotes invasion and tumor progression (Wang, Kang, & Shan, [2013](#mgg3689-bib-0047){ref-type="ref"}). *CD276* normally expresses on APC cells, and is considered as both a positive and a negative costimulatory molecule (Hofmeyer, Ray, & Zang, [2008](#mgg3689-bib-0013){ref-type="ref"}). It promotes T cell‐mediated immune responses and development of acute/chronic rejection (Wang et al., [2005](#mgg3689-bib-0046){ref-type="ref"}), however, diverse functions and contrasting roles of *CD276* remain being explored. Thus, we focused on *CD276* and its ligand, *TREML2*, which could provide an intact signal cascade of positive costimulation (Hashiguchi et al., [2008](#mgg3689-bib-0011){ref-type="ref"}). In this work, we proved that genetic polymorphisms of both *CD276* and *TREML2* were associated with acute rejection of liver transplantation. The evaluations of mRNA and/or protein expression of *CD276* and *TREML2* suggested that the association between SNPs and graft rejections might be due to the expression of *CD276* in *CD3*‐ PBMCs. It seemed that individuals with T alleles at rs2127015 would possess higher *CD276* mRNA level in PBMC, which might lead to more membrane *CD276* expression. We also confirmed a membrane expression of *CD276* in *CD3 *+* *PBMC, where its ligands normally express. However, *TREML2* did not show any mRNA expression difference among alleles. Our results implied the involvement of positive costimulation via *CD276* and *TREML2* in acute rejection.

The diverse functions and contrasting roles of *CD276* may be mainly due to its multiple counterparts on different cells or in different signal pathways. According to the dual role of *CD276* in both positive and negative costimulation effects, *CD276* might also inhibit acute immune reaction posttransplantation probably. Mouse transplantation model ought to facilitate the studies with gene‐edited mouse. However, some studies suggested that *TREML2* might not be a ligand for murine *CD276* (Leitner et al., [2009](#mgg3689-bib-0022){ref-type="ref"}; Yan et al., [2013](#mgg3689-bib-0051){ref-type="ref"}), which makes it more complicated to elucidate the molecular and immune functions of *CD276*.

Meanwhile, the regulation of *CD276* protein production is also obscure. Three kinds of isoforms of *CD276* protein have been reported, transmembrane 4Ig‐*CD276*(4Ig‐*B7‐H3*) (Steinberger et al., [2004](#mgg3689-bib-0040){ref-type="ref"}), transmembrane 2Ig‐*CD276*(2Ig‐*B7‐H3*) (Chen, Hou, Li, Xiong, & Liu, [2011](#mgg3689-bib-0004){ref-type="ref"}), and soluble *CD276*(s*B7‐H3*) (Zhang et al., [2008](#mgg3689-bib-0055){ref-type="ref"}), with different in vivo or cellular distribution patterns, and various biological functions. Meanwhile, soluble 2Ig‐*CD276* isoform could be released in serum by matrix metalloproteinase cleavage of 4Ig‐*CD276* (Zhang et al., [2008](#mgg3689-bib-0055){ref-type="ref"}). At least two forms of alternative spliced *CD276* mRNAs have been found, one translated into soluble *CD276* in hepatocellular carcinoma cells (Chen et al., [2013](#mgg3689-bib-0005){ref-type="ref"}), another translated into intracytoplasmic 2Ig‐*CD276* in monocytes (Yoon et al., [2016](#mgg3689-bib-0052){ref-type="ref"}). Thus, it is possible that several spliced *CD276* mRNAs exist and might be translated into various *CD276* isoforms with different biological functions. Besides mutations in UTRs or exons, SNPs in introns were also proved as alternative splicings and fold changes of certain mRNA forms (Suhy et al., [2014](#mgg3689-bib-0041){ref-type="ref"}; Wang & Sadee, [2016](#mgg3689-bib-0048){ref-type="ref"}). And in this study, we observed an association of increased expression of *CD276* mRNA in rs2127015 T allele carriers. Further studies are needed to elucidate how rs2127015 influences the mRNA expression and whether rs2127015 would lead to alternative splicings.

Several studies confirmed that HBV infection could decrease the incidence of liver graft acute rejection (Crespo, Marino, Navasa, & Forns, [2012](#mgg3689-bib-0007){ref-type="ref"}; Farges et al., [1996](#mgg3689-bib-0010){ref-type="ref"}; Neuberger, [1999](#mgg3689-bib-0028){ref-type="ref"}; Samuel & Kimmoun, [2003](#mgg3689-bib-0035){ref-type="ref"}); however, the molecular mechanism still remains undiscovered. Generally, to prevent the reinfection of HBV postoperation, most centers applied a long‐term administration of high‐dose intramuscular hepatitis B immunoglobulin (HBIG) (Samuel & Kimmoun, [2003](#mgg3689-bib-0035){ref-type="ref"}), while we have developed a safe and efficient substitution therapy which combines lamivudine and low‐dose intramuscular HBIG in our center (Zheng et al., [2006](#mgg3689-bib-0057){ref-type="ref"}). Recent studies suggested that the treatment with immunoglobulin might lead to a decreased risk for rejection and promote allograft acceptance (Bucuvalas, Anand, & Studies of Pediatric Liver Transplantation Research, [2009](#mgg3689-bib-0003){ref-type="ref"}; Tha‐In, Metselaar, Bushell, Kwekkeboom, & Wood, [2010](#mgg3689-bib-0045){ref-type="ref"}). The effect of immune tolerance might result from the inhibition of dendritic cells and provoking *CD4 + FoxP3 + *T cells (Kwekkeboom et al., [2005](#mgg3689-bib-0021){ref-type="ref"}; Tha‐In et al., [2010](#mgg3689-bib-0045){ref-type="ref"}). According to these observations, HBIG administration seemed able to benefit the liver transplant recipients with a better immunosuppression and a reduced acute rejection incidence. However, some researchers claimed that further examinations and studies will be needed to draw the conclusion of the survival benefits from HBIG (Ni & Chang, [2006](#mgg3689-bib-0030){ref-type="ref"}).

The ultimate aim of our risk assessment model was to predict the incidence of acute rejection in advance and individually. The association between risk factors and acute rejection created the opportunity to predict disease risk for principal concern (Kooperberg, LeBlanc, & Obenchain, [2010](#mgg3689-bib-0020){ref-type="ref"}). Thus, primary diagnosis, genetic background, and some other preoperative variables that clinically related were considered in this work. Although the research community is making great progress in association studies, poor conducts have been discussed (Moons, Kengne, Woodward, et al., [2012](#mgg3689-bib-0027){ref-type="ref"}). Most genetic association studies only proved a clinical relevance, but not a clue of when the symptom starts and how severe it develops (Bitetto et al., [2012](#mgg3689-bib-0002){ref-type="ref"}; Jiang et al., [2007](#mgg3689-bib-0017){ref-type="ref"}; Tapirdamaz et al., [2006](#mgg3689-bib-0044){ref-type="ref"}; Zhu et al., [2012](#mgg3689-bib-0058){ref-type="ref"}). It led to a statement for genetic risk prediction studies to strengthen and encompass works with genetic risk factors in translational medicine (Janssens, Ioannidis, van Duijn, Little, & Khoury, [2011](#mgg3689-bib-0016){ref-type="ref"}). Some other works also advocated successive and consecutive steps for researches (Moons, Kengne, Grobbee, et al., [2012](#mgg3689-bib-0026){ref-type="ref"}; Moons, Kengne, Woodward, et al., [2012](#mgg3689-bib-0027){ref-type="ref"}).

So far, our model does not predict whether or when a single recipient will develop acute rejection, however, due to currently limited understanding of genetic factors and other molecules in the immune response of allograft acute rejections. Some works suggested how risk factors would be applied to risk assessment models which follow a procedure of association study, then statistical certification, and finally a formula deduction (Moons, Kengne, Grobbee, et al., [2012](#mgg3689-bib-0026){ref-type="ref"}; Moons, Kengne, Woodward, et al., [2012](#mgg3689-bib-0027){ref-type="ref"}). In this study, a "predictor selection strategy" was applied (Moons, Kengne, Woodward, et al., [2012](#mgg3689-bib-0027){ref-type="ref"}), of which candidate factors that do not contribute usefully will be removed from the model. Then, due to the failure of passing statistical verification, two SNPs of *TREML2*, which are both associated with acute rejection were not included in the model. The other risk factors, rs2127015 and HBV infection, each assigned to a statistically calculated coefficient, could categorize the recipients into three groups. Nevertheless, the incidence of acute rejection in high‐risk group was as much as four to five times to that in low‐risk group, while the incidence of medium‐risk group was close to normal incidence. We also evaluated our model by internal validation. With this model, we would be allowed to treat recipients with different immunosuppressive regimen. Therefore, recipients categorized into the high‐risk group will receive additional surveillance of immunosuppression both immunologically and pharmacodynamically (Sawitzki, Schlickeiser, Reinke, & Volk, et al., [2011](#mgg3689-bib-0037){ref-type="ref"}), whereas recipients in the low‐risk group should avoid excessive immunosuppression. To refine our model, integrating more risk factors, statistically or experimentally proved, should be proceeded.

In conclusion, by combining biomarkers, such as genetic polymorphism, with other risk factors, we deduced a semiquantitative risk assessment model, which would benefit recipients with an individualized immunosuppression for clinical cares.
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